Compare PRLD & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRLD | PCM |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 82.0M |
| IPO Year | 2020 | N/A |
| Metric | PRLD | PCM |
|---|---|---|
| Price | $1.68 | $6.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 29.1K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.68% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.00 | N/A |
| 52 Week Low | $0.61 | $6.88 |
| 52 Week High | $4.22 | $10.20 |
| Indicator | PRLD | PCM |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 42.89 |
| Support Level | $1.32 | $6.08 |
| Resistance Level | $1.69 | $6.27 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 91.02 | 47.38 |
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.